ArticleMolecular therapy : the journal of the American Society of Gene Therapy2013
Targeted coating with antigenic peptide renders tumor cells susceptible to CD8(+) T cell-mediated killing.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- A Spike-Linked HPV16 E7 DNA Vaccine Induces Potent Antitumor and Anti-Spike Immune Responses.International journal of molecular sciences · 2026Article
- A Universal Strategy of Anti-Tumor mRNA Vaccine by Harnessing "Off-the-Shelf" Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- CD312 Promotes Paediatric Acute Lymphoblastic Leukaemia Through GNA15-Mediated Non-Classical GPCR Signalling Pathway.Journal of cellular and molecular medicine · 2024Article
- Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells.Cancer immunology, immunotherapy : CII · 2024Article
- Antibody-mediated delivery of viral epitopes to redirect EBV-specific CD8Cancer gene therapy · 2024Article
- Comparison of methods generating antibody-epitope conjugates for targeting cancer with virus-specific T cells.Frontiers in immunology · 2023Article
- Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8Molecular cancer · 2022Article
- Control of Tumors by Antigen-Specific CD8Journal of immunology research · 2022Article
- Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment.Nature communications · 2020Article
- Sensitization of Tumors for Attack by Virus-Specific CD8+ T-Cells Through Antibody-Mediated Delivery of Immunogenic T-Cell Epitopes.Frontiers in immunology · 2019Article
- Antibodies conjugated with viral antigens elicit a cytotoxic T cell response against primary CLL ex vivo.Leukemia · 2019Article
- Article
- Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment.PloS one · 2014Article
- Control of spontaneous ovarian tumors by CD8+ T cells through NKG2D-targeted delivery of antigenic peptide.Cell & bioscience · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The potency of immunotherapies targeting endogenous tumor antigens is hindered by immune tolerance. We created a therapeutic agent comprised of a tumor-homing module fused to a functional domain capable of selectively rendering tumor cells sensitive to foreign antigen-specific CD8(+) T cell-mediated immune attack, and thereby, circumventing concerns for immune tolerance. The tumor-homing module is comprised of a single-chain variable fragment (scFv) that specifically binds to mesothelin (Meso), which is commonly overexpressed in human cancers, including ovarian tumors. The functional domain is comprised of the Fc portion of IgG2a protein and foreign immunogenic CD8(+) T cell epitope flanked by furin cleavage sites (R), which can be recognized and cleaved by furin that is highly expressed in the tumor microenvironment. We show that our therapeutic protein specifically loaded antigenic epitope onto the surface of mesothelin-expressing tumor cells, rendering tumors susceptible to antigen-specific cytotoxic CD8(+) T lymphocytes (CTL)-mediated killing in vitro and in vivo. Our findings have important implications for bypassing immune tolerance to enhance cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.